Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125303841 | 12530384 | 1 | I | 20160624 | 20160706 | 20160706 | EXP | US-LUPIN PHARMACEUTICALS INC.-2016-03019 | LUPIN | HOFMANN M, OVERMAN M, NATES J. ACUTE BENZODIAZEPINE TOXICITY EXACERBATED BY CONCOMITANT ORAL OLANZAPINE. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY. 2016 APR;14(4):178-179. | 61.00 | YR | F | Y | 0.00000 | 20160706 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125303841 | 12530384 | 1 | PS | LORAZEPAM. | LORAZEPAM | 1 | Oral | 2-3 TIMES | UNKNOWN | 91407 | 1 | MG | |||||||
| 125303841 | 12530384 | 2 | SS | LORAZEPAM. | LORAZEPAM | 1 | UNKNOWN | 91407 | |||||||||||
| 125303841 | 12530384 | 3 | SS | OLANZAPINE. | OLANZAPINE | 1 | Oral | 10 MG | UNKNOWN | 0 | |||||||||
| 125303841 | 12530384 | 4 | SS | OLANZAPINE. | OLANZAPINE | 1 | UNKNOWN | 0 | |||||||||||
| 125303841 | 12530384 | 5 | C | FOLFOX | FLUOROURACILLEUCOVORIN CALCIUMOXALIPLATIN | 1 | Intravenous (not otherwise specified) | (OXALIPLATIN 60 MG/M2 INTRAVENOUS (IV) OVER 2 HOURS, 5-FU 2000 MG/M2 IV OVER 46 HOURS) | 0 | ||||||||||
| 125303841 | 12530384 | 6 | C | FOLFOX | FLUOROURACILLEUCOVORIN CALCIUMOXALIPLATIN | 1 | 0 | ||||||||||||
| 125303841 | 12530384 | 7 | C | FOLFOX | FLUOROURACILLEUCOVORIN CALCIUMOXALIPLATIN | 1 | 0 | ||||||||||||
| 125303841 | 12530384 | 8 | C | FOLFOX | FLUOROURACILLEUCOVORIN CALCIUMOXALIPLATIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125303841 | 12530384 | 1 | Nausea |
| 125303841 | 12530384 | 2 | Anxiety |
| 125303841 | 12530384 | 3 | Prophylaxis of nausea and vomiting |
| 125303841 | 12530384 | 4 | Anxiety |
| 125303841 | 12530384 | 5 | Pancreatic carcinoma |
| 125303841 | 12530384 | 6 | Metastases to lung |
| 125303841 | 12530384 | 7 | Metastases to liver |
| 125303841 | 12530384 | 8 | Metastases to lymph nodes |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125303841 | 12530384 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125303841 | 12530384 | Condition aggravated | |
| 125303841 | 12530384 | Delirium | |
| 125303841 | 12530384 | Drug interaction | |
| 125303841 | 12530384 | Hypotension | |
| 125303841 | 12530384 | Respiratory depression | |
| 125303841 | 12530384 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |